



In the competition between men and microbes, a
golden age probably is behind us. During the last several
decades, there have been major advances in the therapy and
prevention of infectious diseases, including better hygienic
conditions, isolation procedures, immunizations, and antibio-
tics. These breakthroughs have led to a progressive, sus-
tained decrease in the morbidity and mortality of infections,
such that the World Health Organization could propose
“health for all in the year 2000” as an ambitious but
apparently achievable target.
We now are becoming somewhat disillusioned. The
acquired immunodeficiency syndrome represents the most
striking example of the unexpected emergence of an
unknown virus, exploding from a remote jungle and circling
the globe within a few years. However, many other “new”
microbes and “new” diseases have been identified during
the last 20 years: a bacterium producing a worldwide
l3-lactam-resistant p eumonia (Legionella  pneumophila), an
agent associated with gastric ulcers and cancer (Helico-
batter  pylori),  the toxic shock syndrome (“new” strains of
Staphylococcus aureus),  the most prevalent vector-borne
disease in the United States (Borrelia  burgdolferi,  causing
Lyme disease), recently recognized viral causes of hemor-
rhagic fevers, the new Hantavirus that causes a respiratory
distress syndrome, and a bacterial agent producing atypical
pneumonia potentially associated with arteriosclerosis
(Chlamydia  pneumoniae).  The list continues to grow each
year. In addition, some older plagues remain present or have
made new progress: antibiotic-resistant tuberculosis has
struck populations suffering from malnutrition or HIV infec-
tion, salmonellosis has advanced in both developed and
developing countries, highly virulent strains of cholera have
emerged in Bangladesh, and diphtheria has returned to
Eastern Europe.
The hospital environment is not exempt from new and
difficult problems. In recent years, difficult-to-treat gram-
positive bacteria (in particular, methicillin-resistant staphylo-
cocci or Enterococcus faecium and fungi) have become
increasingly important. Gram-negative bacteria remain a
major cause of mortality, with the emergence of multir sis-
tant strains, such as Enterobacter cloacae, Pseudomonas
aeruginosa resistant to carbapenems and quinolones, Entero-
bact iaceae resistant to extended-spectrum p-la amases,
and Xanthomonas maltophilia. We must formulate imagina-
tive answers to face the new infectious crisis; this will
require both a global approach and multiple local actions.
Some microbial cauldrons offer no ready solutions in
the f reseeable future: booming and uncontrolled urbaniza-
ti n, the proliferation of pockets of misery in rich countries,
and multiplication of new wars all around the planet, for
example. But some other challenges can b  met: more
judicious use of antibiotics, the development of new vaccines
and anti-infectious drugs, and continued or improved atten-
tion to hygienic practices, to name a few. Obviously, there is
an ur ent need for new ideas, discussions, and concerted
efforts. The International Conference on the Prevention of
Infections (CIPI) has been created for that purpose.
Ev ry other spring since 1990, individuals and societies
involved in the prevention of infection are invited to meet in
Nice, France. Every aspect of the vast field of prevention is
discussed: public health, intensive care units, pediatrics,
surgery, microbiology, infectious diseases, and infection
control. The meeting is held under the auspices of several
pr stigious societies sharing the same concerns, and approx-
imately 1,500 participants gather together, about 80% of
them Europeans.
Thi  year, CIPI and Infection Control and Hospital
Epidemiology (ICHE) have decided to collaborate and to
invite manuscripts from presenters whose work was perti-
nent to the scope of ZCHE. The results of these efforts are
presented here. We hope that the reader will find stimulat-
ing the discussions on some of the burning questions
fe tured in CIPI ‘94: How do we improve mortality in the
ICUs? H w do we limit the spread of antibiotic resistance?
What pertinent information can we expect from molecular
pidemiology? How do we prevent cross-transmission in
ICUs, operating rooms, and long-term care facilities? Is
b cille Calmette-Guerin useful in developed countries? Is
prevention of nosocomial infections economically sound?
We hope that the ICHE-CIPI collaboration will continue
in the future and invite you to attend CIPI ‘96, to be held in
April 1996, in Nice, of course!
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